§ Mr. Murphy
asked the Secretary of State for Social Services if the revised National Health Service pharmaceutical price regulation scheme will contain safeguards to ensure adequate investment in new drug development.
§ Mr. Kenneth Clarke
A company's expenditure on research and development will continue to be accepted. within reasonable limits, as a legitimate cost in the pricing of NHS medicines and will influence its approved profit target under the Pharmaceutical Price Regulation Scheme.